
|Videos|January 24, 2022
Assessing the Burden of Atherosclerotic Cardiovascular Disease in the US
Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses the burden of ASCVD in the country today.
Advertisement
Pharmacy Times interviewed Norman Lepor, MD, a Los Angeles-based cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), on the burden of atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol management.
During the interview, Lepor discussed the burden of ASCVD in the country today.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Bepirovirsen Shows Breakthrough Potential for Functional Cure in Chronic Hepatitis B
2
Lingering Muscle Damage After Weight Restoration in Anorexia Nervosa May Require Long-Term Care
3
Pharmacist-Led Dietary Guidance Supports Kidney Health
4
Adapting AI Prescreening Approaches to Advance 340B Operations
5














































































































































































































